Technology Bundle ID: TAB-3245

Zika Virus NS1 Protein Monoclonal Antibodies for Research, Development, and Novel Diagnostics

Request More Info
Licensing Contact:
Primary Inventors: 
Jason Goldstein (CDC)
Co-Inventors: 
Dennis Bagarozzi (CDC)
Development Stage: 
Pre-Clinical (in vitro)
Institute or Center: 
CDC

Zika virus is a flavivirus that is spread by the bite of infected Aedes mosquitoes. The current outbreak and swift dissemination/spread of Zika virus (ZIKV) and its linkage to birth defects and neurological syndromes has prompted the development of novel diagnostic tests. Because ZIKV is serologically similar to other flaviviruses such as dengue virus (DNV), cross-reactivity occurs in diagnostic tests and can result in misdiagnoses. This is especially evident in populations that live in dengue-endemic regions or have received heterologous flaviviral vaccines (i.e., yellow fever 17D). CDC researchers have developed seven monoclonal antibodies (mAbs) that are highly specific to the Zika virus non-structural protein 1 (NS1 protein) without cross-reactivity to other flaviviruses. These antibodies can be used to create rapid and more specific diagnostic tests. Data to support ZIKV-specific and DENV-specific mAbs include immunofluorescence, immunoblots of r-protein and viral lysates, recombinant proteins in label-free binding, and indirect ELISA studies. Platforms such as lateral flow diagnostics and nanotechnology devices capable of interfacing with smartphone/digital devices are possible.

Applications:
  • Zika diagnostic immunoassay for clinical sample and tissue confirmation of Zika virus
  • Zika immunodiagnostic reagent
  • Differentiation between Zika virus and other flaviviruses
  • Platforms such as lateral flow diagnostics and nanotechnology devices capable of interfacing with smartphone/digital devices are possible
  • Research and development
Advantages:
  • Higher sensitivity than many commercially available and academic available antibodies for Zika
  • Differentiate between Zika virus and other flaviviruses such as dengue, West Nile virus, and yellow fever virus
  • Differentiate between Zika virus and prior vaccinations to dengue or yellow fever virus which can impact Zika test results

Patents

PCT Application PCT/US2018/018709
Filed on 2018-02-20
US Application 62/460,635
Filed on 2017-02-17

Updated

Feb 9, 2018

Data Source: 
tts